Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms
The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to moni...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Novotny, R. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance - Chen, Anyi ELSEVIER, 2023, an international journal of animal reproduction, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:83 ; year:2015 ; number:7 ; day:15 ; month:04 ; pages:1188-1193 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.theriogenology.2014.12.026 |
|---|
| Katalog-ID: |
ELV03432075X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV03432075X | ||
| 003 | DE-627 | ||
| 005 | 20230625200611.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.theriogenology.2014.12.026 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015002000001.pica |
| 035 | |a (DE-627)ELV03432075X | ||
| 035 | |a (ELSEVIER)S0093-691X(14)00702-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 590 | |
| 082 | 0 | 4 | |a 590 |q DE-600 |
| 082 | 0 | 4 | |a 070 |a 004 |q VZ |
| 084 | |a LING |q DE-30 |2 fid | ||
| 084 | |a 54.00 |2 bkl | ||
| 084 | |a 53.71 |2 bkl | ||
| 100 | 1 | |a Novotny, R. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| 264 | 1 | |c 2015transfer abstract | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. | ||
| 520 | |a The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. | ||
| 650 | 7 | |a Testosterone |2 Elsevier | |
| 650 | 7 | |a Male cat |2 Elsevier | |
| 650 | 7 | |a GnRH-agonist |2 Elsevier | |
| 650 | 7 | |a Histologic evaluation |2 Elsevier | |
| 650 | 7 | |a Semen collection |2 Elsevier | |
| 650 | 7 | |a Testis size |2 Elsevier | |
| 700 | 1 | |a Vitasek, R. |4 oth | |
| 700 | 1 | |a Bartoskova, A. |4 oth | |
| 700 | 1 | |a Cizek, P. |4 oth | |
| 700 | 1 | |a Prinosilova, P. |4 oth | |
| 700 | 1 | |a Novakova, K. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Chen, Anyi ELSEVIER |t Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance |d 2023 |d an international journal of animal reproduction |g Amsterdam [u.a.] |w (DE-627)ELV009476539 |
| 773 | 1 | 8 | |g volume:83 |g year:2015 |g number:7 |g day:15 |g month:04 |g pages:1188-1193 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.theriogenology.2014.12.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-LING | ||
| 912 | |a SSG-OPC-BBI | ||
| 936 | b | k | |a 54.00 |j Informatik: Allgemeines |q VZ |
| 936 | b | k | |a 53.71 |j Theoretische Nachrichtentechnik |q VZ |
| 951 | |a AR | ||
| 952 | |d 83 |j 2015 |e 7 |b 15 |c 0415 |h 1188-1193 |g 6 | ||
| 953 | |2 045F |a 590 | ||
| author_variant |
r n rn |
|---|---|
| matchkey_str |
novotnyrvitasekrbartoskovaacizekpprinosi:2015----:zopriwtvraltsiuahsooyfe7otsframnwt |
| hierarchy_sort_str |
2015transfer abstract |
| bklnumber |
54.00 53.71 |
| publishDate |
2015 |
| allfields |
10.1016/j.theriogenology.2014.12.026 doi GBVA2015002000001.pica (DE-627)ELV03432075X (ELSEVIER)S0093-691X(14)00702-X DE-627 ger DE-627 rakwb eng 590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Novotny, R. verfasserin aut Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Elsevier Vitasek, R. oth Bartoskova, A. oth Cizek, P. oth Prinosilova, P. oth Novakova, K. oth Enthalten in Elsevier Science Chen, Anyi ELSEVIER Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance 2023 an international journal of animal reproduction Amsterdam [u.a.] (DE-627)ELV009476539 volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 https://doi.org/10.1016/j.theriogenology.2014.12.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 83 2015 7 15 0415 1188-1193 6 045F 590 |
| spelling |
10.1016/j.theriogenology.2014.12.026 doi GBVA2015002000001.pica (DE-627)ELV03432075X (ELSEVIER)S0093-691X(14)00702-X DE-627 ger DE-627 rakwb eng 590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Novotny, R. verfasserin aut Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Elsevier Vitasek, R. oth Bartoskova, A. oth Cizek, P. oth Prinosilova, P. oth Novakova, K. oth Enthalten in Elsevier Science Chen, Anyi ELSEVIER Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance 2023 an international journal of animal reproduction Amsterdam [u.a.] (DE-627)ELV009476539 volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 https://doi.org/10.1016/j.theriogenology.2014.12.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 83 2015 7 15 0415 1188-1193 6 045F 590 |
| allfields_unstemmed |
10.1016/j.theriogenology.2014.12.026 doi GBVA2015002000001.pica (DE-627)ELV03432075X (ELSEVIER)S0093-691X(14)00702-X DE-627 ger DE-627 rakwb eng 590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Novotny, R. verfasserin aut Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Elsevier Vitasek, R. oth Bartoskova, A. oth Cizek, P. oth Prinosilova, P. oth Novakova, K. oth Enthalten in Elsevier Science Chen, Anyi ELSEVIER Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance 2023 an international journal of animal reproduction Amsterdam [u.a.] (DE-627)ELV009476539 volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 https://doi.org/10.1016/j.theriogenology.2014.12.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 83 2015 7 15 0415 1188-1193 6 045F 590 |
| allfieldsGer |
10.1016/j.theriogenology.2014.12.026 doi GBVA2015002000001.pica (DE-627)ELV03432075X (ELSEVIER)S0093-691X(14)00702-X DE-627 ger DE-627 rakwb eng 590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Novotny, R. verfasserin aut Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Elsevier Vitasek, R. oth Bartoskova, A. oth Cizek, P. oth Prinosilova, P. oth Novakova, K. oth Enthalten in Elsevier Science Chen, Anyi ELSEVIER Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance 2023 an international journal of animal reproduction Amsterdam [u.a.] (DE-627)ELV009476539 volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 https://doi.org/10.1016/j.theriogenology.2014.12.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 83 2015 7 15 0415 1188-1193 6 045F 590 |
| allfieldsSound |
10.1016/j.theriogenology.2014.12.026 doi GBVA2015002000001.pica (DE-627)ELV03432075X (ELSEVIER)S0093-691X(14)00702-X DE-627 ger DE-627 rakwb eng 590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Novotny, R. verfasserin aut Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms 2015transfer abstract 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Elsevier Vitasek, R. oth Bartoskova, A. oth Cizek, P. oth Prinosilova, P. oth Novakova, K. oth Enthalten in Elsevier Science Chen, Anyi ELSEVIER Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance 2023 an international journal of animal reproduction Amsterdam [u.a.] (DE-627)ELV009476539 volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 https://doi.org/10.1016/j.theriogenology.2014.12.026 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI 54.00 Informatik: Allgemeines VZ 53.71 Theoretische Nachrichtentechnik VZ AR 83 2015 7 15 0415 1188-1193 6 045F 590 |
| language |
English |
| source |
Enthalten in Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance Amsterdam [u.a.] volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 |
| sourceStr |
Enthalten in Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance Amsterdam [u.a.] volume:83 year:2015 number:7 day:15 month:04 pages:1188-1193 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Informatik: Allgemeines Theoretische Nachrichtentechnik |
| institution |
findex.gbv.de |
| topic_facet |
Testosterone Male cat GnRH-agonist Histologic evaluation Semen collection Testis size |
| dewey-raw |
590 |
| isfreeaccess_bool |
false |
| container_title |
Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance |
| authorswithroles_txt_mv |
Novotny, R. @@aut@@ Vitasek, R. @@oth@@ Bartoskova, A. @@oth@@ Cizek, P. @@oth@@ Prinosilova, P. @@oth@@ Novakova, K. @@oth@@ |
| publishDateDaySort_date |
2015-01-15T00:00:00Z |
| hierarchy_top_id |
ELV009476539 |
| dewey-sort |
3590 |
| id |
ELV03432075X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV03432075X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625200611.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.theriogenology.2014.12.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015002000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV03432075X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0093-691X(14)00702-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">590</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">070</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.71</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Novotny, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Testosterone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Male cat</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GnRH-agonist</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Histologic evaluation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Semen collection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Testis size</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vitasek, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bartoskova, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cizek, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prinosilova, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Novakova, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Chen, Anyi ELSEVIER</subfield><subfield code="t">Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance</subfield><subfield code="d">2023</subfield><subfield code="d">an international journal of animal reproduction</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009476539</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:83</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:7</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1188-1193</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.theriogenology.2014.12.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.00</subfield><subfield code="j">Informatik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.71</subfield><subfield code="j">Theoretische Nachrichtentechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">83</subfield><subfield code="j">2015</subfield><subfield code="e">7</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">1188-1193</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">590</subfield></datafield></record></collection>
|
| author |
Novotny, R. |
| spellingShingle |
Novotny, R. ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| authorStr |
Novotny, R. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009476539 |
| format |
electronic Article |
| dewey-ones |
590 - Animals (Zoology) 070 - News media, journalism & publishing 004 - Data processing & computer science |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size Elsevier |
| topic |
ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size |
| topic_unstemmed |
ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size |
| topic_browse |
ddc 590 ddc 070 fid LING bkl 54.00 bkl 53.71 Elsevier Testosterone Elsevier Male cat Elsevier GnRH-agonist Elsevier Histologic evaluation Elsevier Semen collection Elsevier Testis size |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r v rv a b ab p c pc p p pp k n kn |
| hierarchy_parent_title |
Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance |
| hierarchy_parent_id |
ELV009476539 |
| dewey-tens |
590 - Animals (Zoology) 070 - News media, journalism & publishing 000 - Computer science, knowledge & systems |
| hierarchy_top_title |
Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009476539 |
| title |
Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| ctrlnum |
(DE-627)ELV03432075X (ELSEVIER)S0093-691X(14)00702-X |
| title_full |
Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| author_sort |
Novotny, R. |
| journal |
Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance |
| journalStr |
Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science 000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
1188 |
| author_browse |
Novotny, R. |
| container_volume |
83 |
| physical |
6 |
| class |
590 590 DE-600 070 004 VZ LING DE-30 fid 54.00 bkl 53.71 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Novotny, R. |
| doi_str_mv |
10.1016/j.theriogenology.2014.12.026 |
| dewey-full |
590 070 004 |
| title_sort |
azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| title_auth |
Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| abstract |
The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. |
| abstractGer |
The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. |
| abstract_unstemmed |
The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING SSG-OPC-BBI |
| container_issue |
7 |
| title_short |
Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms |
| url |
https://doi.org/10.1016/j.theriogenology.2014.12.026 |
| remote_bool |
true |
| author2 |
Vitasek, R. Bartoskova, A. Cizek, P. Prinosilova, P. Novakova, K. |
| author2Str |
Vitasek, R. Bartoskova, A. Cizek, P. Prinosilova, P. Novakova, K. |
| ppnlink |
ELV009476539 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth |
| doi_str |
10.1016/j.theriogenology.2014.12.026 |
| up_date |
2024-07-06T20:50:20.101Z |
| _version_ |
1803864265302474752 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV03432075X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625200611.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.theriogenology.2014.12.026</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015002000001.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV03432075X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0093-691X(14)00702-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">590</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">070</subfield><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.71</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Novotny, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The main aim of the study was to assess whether the longer use of a GnRH-agonist implant (deslorelin 4.7 mg, Suprelorin) in toms would lead to the suppression of spermatogenesis comparable with histologic appearance in juvenile animals as was previously described in dogs. The other aims were to monitor the progression of the testes size decrease and development of azoospermia 5 to 7 months after treatment with a GnRH-agonist implant. In animals, 5, 6, and 7 months after GnRH-agonist implant insertion, variable histological appearance of germinal epithelium was found, when tubules with elongating spermatids, round spermatids, spermatocytes, and spermatogonia as the most developed germinal cells were found in each group of toms. In all male cats, 5, 6, and 7 months after implant insertion, testosterone concentrations and testes size significantly differed between the first and the last visit. All animals, except one tom castrated 5 months after implant insertion, developed complete azoospermia. However, in this tom, all spermatozoa were immotile. Treatment with the subcutaneous GnRH-agonist implant was well tolerated, and no treatment-related adverse effects were noted. These results reported the efficacy of 4.7-mg deslorelin implant (Suprelorin) during its 7 months of use. The complete azoospermia confirms its contraceptive effect. However, the histologic evaluation revealed a great individual variability in the degree of spermatogenic suppression. The question as to whether spermatogenesis in toms can be suppressed in all males to the level of spermatogonia/primary spermatocytes after prolonged exposure to deslorelin has yet to be answered.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Testosterone</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Male cat</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GnRH-agonist</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Histologic evaluation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Semen collection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Testis size</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vitasek, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bartoskova, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cizek, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Prinosilova, P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Novakova, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Chen, Anyi ELSEVIER</subfield><subfield code="t">Multi-source monitoring information fusion method for dam health diagnosis based on Wasserstein distance</subfield><subfield code="d">2023</subfield><subfield code="d">an international journal of animal reproduction</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009476539</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:83</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:7</subfield><subfield code="g">day:15</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:1188-1193</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.theriogenology.2014.12.026</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-BBI</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.00</subfield><subfield code="j">Informatik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.71</subfield><subfield code="j">Theoretische Nachrichtentechnik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">83</subfield><subfield code="j">2015</subfield><subfield code="e">7</subfield><subfield code="b">15</subfield><subfield code="c">0415</subfield><subfield code="h">1188-1193</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">590</subfield></datafield></record></collection>
|
| score |
7.3974752 |